中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

36 records (took 0.034 seconds)

    Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
    1.
    发明授权
    Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release 有权

    公开(公告)号：US11337919B2

    公开(公告)日：2022-05-24

    申请号：US16955377

    申请日：2018-12-18

    Applicant: Tris Pharma, Inc.

    Inventor： Paras Rameshlal Jain ,  Sachin Vasant Chaudhari

    IPC: A61K9/00 ,  A61K31/00 ,  A61K47/58 ,  A61K9/16 ,  A61K45/06

    Abstract: An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one drug in an immediate release pulse release form; (b) at least one drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one drug in the stomach for at least about 3 hours, provided that the composition does not include a gamma hydroxybutyrate and its salts, hydrates, tautomers, or solvates, or complexes thereof.

    Compositions comprising AAV expressing dual antibody constructs and uses thereof
    3.
    发明授权
    Compositions comprising AAV expressing dual antibody constructs and uses thereof 有权

    公开(公告)号：US10138295B2

    公开(公告)日：2018-11-27

    申请号：US15310555

    申请日：2015-05-13

    Applicant: The Trustees of the University of Pennsylvania

    Inventor： James M. Wilson ,  Anna Tretiakova

    IPC: A61K48/00 ,  C12N7/00 ,  C12Q1/68 ,  A61K38/00 ,  C07K16/00 ,  C07K16/10 ,  C12N15/86 ,  A61K39/00

    Abstract: A recombinant adeno-associated virus (AAV) having an AAV capsid and packaged therein a heterologous nucleic acid which expresses two functional antibody constructs in a cell is described. Also described are antibodies comprising a heavy chain and a light chain from a heterologous antibody. In one embodiment, the antibodies are co-expressed from a vector containing: a first expression cassette which encodes at least a first open reading frame (ORF) for a first immunoglobulin under the control of regulatory control sequences which direct expression thereof; and a second expression cassette which comprises a second ORF, a linker, and a third ORF under the control of regulatory control sequences which direct expression thereof, wherein the second and third ORF encode for a second and third immunoglobulin construct. The vector co-expressing these two antibody constructs is in one embodiment an AAV, in which the 5′ and 3′ ITRs flank the expression cassettes and regulatory sequences.

    Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
    5.
    发明授权
    Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release 有权

    公开(公告)号：US11337920B2

    公开(公告)日：2022-05-24

    申请号：US16955392

    申请日：2018-12-18

    Applicant: Tris Pharma, Inc.

    Inventor： Paras Rameshlal Jain ,  Sachin Vasant Chaudhari

    IPC: A61K9/00 ,  A61K31/19 ,  A61K47/58 ,  A61K9/16 ,  A61K9/50

    Abstract: An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses is provided. The composition contains, at a minimum, (a) at least one GHB drug in a first pulse release which releases in less than about 3 hours; (b) at least one GHB drug in a delayed trigger release form; (c) at least one non-toxic gas generating agent; and (d) a RAFT system, wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug of (a) and (b) and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a dual pulse system wherein at least the second pulse is a trigger pulse and which retains the at least one GHB drug in the stomach for at least about 3 hours.

    Compositions, methods and microfluidics device for telomerase based in vitro diagnostic assays for detecting circulating tumor cells (CTC)
    9.
    发明授权
    Compositions, methods and microfluidics device for telomerase based in vitro diagnostic assays for detecting circulating tumor cells (CTC) 有权

    公开(公告)号：US10338071B2

    公开(公告)日：2019-07-02

    申请号：US15812105

    申请日：2017-11-14

    Applicant: The Trustees of the University of Pennsylvania

    Inventor： Stephen M. Hahn ,  Jay F. Dorsey ,  Gary D. Kao ,  Emigdio Reyes

    IPC: G01N33/574 ,  C12Q1/6897 ,  C12Q1/68 ,  G01N33/543 ,  B01L3/00 ,  G01N30/52

    Abstract: A repeatable method for detecting circulating tumor cells in vitro is provided. The method involves combining a test sample from a patient suspected of having circulating tumor cells, and a non-lytic adenoviral system, and culture media for the cells. The adenoviral system utilizes (i) a first replication-defective adenoviral particle in which an expression cassette is packaged, said expression cassette comprising an adenoviral 5′ and 3′ ITRs and a tumor-specific promoter; and (ii) a coding sequence for a reporter protein which is expressed in the presence of circulating tumor cells, and an adenoviral 3′ ITR. The test sample and the non-lytic adenoviral system are incubated for a sufficient time to permit expression of the reporter protein, and measuring reporter protein expression in the test samples, whereby presence of reporter expression indicates the presence of circulating tumor cells in the sample. Because the system is non-lytic, the testing can be repeated on the cells which remain viable in culture. Also provided is a method for enriching test samples having circulating tumor cells and a microfluidics device suitable for CTC-specification identification and enumeration.

Patent Agency Ranking